NCT07590336RecruitingPhase 1/2
68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma
Study on the Clinical Application of GPC3-targeting 68Ga-NYM207 PET/CT in Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
This is a prospective, single-center, single-arm, phase I/II study designed to evaluate (1) the safety, tolerability, and imaging characteristics of 68Ga-NYM207 (Phase A), and (2) the diagnostic performance of 68Ga-NYM207 in detecting hepatocellular carcinoma (HCC) (Phase B). This study will provide critical insights into the performance of 68Ga-NYM207 PET/CT as a non-invasive imaging tool for the detection of HCC.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 6 May 2026
- Start date
- 11 Jun 2026
- Primary completion date
- 1 Apr 2027
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07590336
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 100
- From 11 Jun 2026 to the primary completion date, 1 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- On treatment with anti-tumor drugs targeting GPC3;
Other illness
- Any condition deemed by the investigator to interfere with study results or increase participant risk.
Other
- Pregnancy or lactation;
- Severe claustrophobia;
Who the study is looking for
- ≥18 years of age and of either gender;
- Written informed consent provided for participation in the trial;
- At least one of the following indications should be applied:
- scheduled for surgical resection or biopsy of the liver mass suspected of HCC within one month;
- with a history of HCC, recurrence or metastasis during follow-up (based on laboratory examination or typical appearance of imaging data including conventional imaging or 18F-FDG PET/CT scan);
- Willing and able to follow schedule visits, treatment plans and laboratory tests.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.